政策与信息披露
AbbVie is committed to being fully transparent and compliant with our policies and disclosures.\r\n"}}" id="text-063b6e6275" class="cmp-text">
AbbVie致力于完全透明,符合我们的政策和信息披露。
我们的政策
我们的公司政治参与的政策
Our engagement with the U.S. Federal and State governments\r\n
AbbVie’s public policy engagement is guided by the following principles:
\r\n- \r\n
- AbbVie is committed to transparency and is guided by our Code of Business Conduct in all public policy engagement. \r\n
- AbbVie pursues activities that shape policies to benefit patients, with a focus on improving patient access to new medical advances. \r\n
- AbbVie federal and state government affairs representatives participate in annual ethics and legal training on political engagement. \r\n
Furthermore, AbbVie does not;
\r\n- \r\n
- provide political contributions in anticipation of, in recognition of, or in return for an official act; \r\n
- seek or receive direct or indirect reimbursements for personal political contributions or expenses; \r\n
- pressure or coerce fellow employees to make personal political contributions; or, \r\n
- reward employees or make employment decisions based in whole or in part on that employee’s personal political contributions. \r\n
Our Federal Government Affairs office in Washington, D.C. is responsible for advocacy activities with the U.S. Congress and the federal government. Advocacy at the U.S. state level is managed by our State Government Affairs function. AbbVie also hires outside firms that can provide expertise on our key policy issues. AbbVie does not currently make direct expenditures for U.S. federal and state grassroots lobbying communications to the general public. Additionally, AbbVie does not currently contribute funds intended for use in elections to 501(c)(4) organizations but, should such a contribution be made in the future, it would be listed with AbbVie’s other corporate political contributions.
\r\nThe AbbVie Board of Directors’ public policy and sustainability committee exercises oversight of AbbVie’s political expenditures and lobbying activities, as specifically enumerated in the committee’s charter, and which are further governed by the Committee’s approved policy on political contributions. The public policy and sustainability committee and AbbVie’s senior management review these activities and expenditures on a regular basis. In the United States, in compliance with the Lobbying Disclosure Act, AbbVie will file a quarterly report that includes: (i) total federal lobbying expenditures, (ii) the name of the specific piece of legislation or subject that was the topic of communication, (iii) disclosure of AbbVie individuals who lobbied on behalf of AbbVie, and (iv) identification of the legislative body or executive branch that was contacted. This report incorporates expenses associated with lobbying the federal government, including our Federal Government Affairs office and the portion of trade association dues associated with federal lobbying. Our latest federal lobbying disclosure filings can be found on the U.S. Senate Office of Public Records website and the U.S. House of Representatives Office of the Clerk website. We file similar publicly-available lobbying reports with states, as required by law, available here.
\r\n
AbbVie advocates on a range of issues in the United States, including:
\r\n- \r\n
- Advancing patient access to drug therapy as prescribed by their clinician \r\n
- Reducing patient out of pocket costs \r\n
- Strong intellectual property protections \r\n
- Rewarding innovation \r\n
The Senior Vice President, Government Affairs, exercises oversight of all external vendors that lobby on AbbVie’s behalf and periodically updates the Public Policy and Sustainability Committee of the AbbVie Board of Directors regarding AbbVie’s lobbying priorities.
\r\nOur report on political contributions
\r\n
AbbVie participates in the political process by contributing to U.S. federal, state and local candidates and political organizations. We support candidates and organizations that understand how government actions can affect patients’ access to medical advances and that will work to promote an environment that fosters continued medical progress. As discussed in more detail below, this support comes via two mechanisms: (1) corporate political contributions direct from AbbVie and (2) political contributions directed from the AbbVie Political Action Committee.
\r\nContributions to office holders and candidates are bipartisan and based on several criteria: policy positions that reflect AbbVie’s interests related to key advocacy priorities; representation of geographic areas where AbbVie employees and facilities are located; relevant legislative committee assignments; ability to be elected; and need for financial assistance. The private political preferences of AbbVie’s executives or other employees do not play a role in how corporate political funds are spent.
\r\nThe Senior Vice President, Government Affairs, reviews and approves all corporate political contributions at the recommendation of AbbVie’s Government Affairs function to ensure these contributions are consistent with the company’s guidelines and in accordance with applicable laws as required by the Corporate Political Contributions Policy. The Public Policy and Sustainability Committee of the AbbVie Board of Directors reviews the Corporate Political Contributions Policy every three years or more frequently and is periodically briefed on the political contributions made by AbbVie.
\r\nAn internal Political Action Committee (PAC) Board of Directors guides the AbbVie PAC. The PAC Board is chaired by the Senior Vice President, Government Affairs and is comprised of at least twelve senior leaders representing a broad range of functions within AbbVie. The AbbVie PAC Board members hold a wide range of experiences and perspectives that inform AbbVie PAC activities. A direct link to AbbVie’s PAC contributions can be viewed on the Federal Election Commission website here.
\r\n
Both AbbVie’s PAC and direct corporate political contributions support a wide range of candidates and committees representing both major political parties and independent candidates and committees. For example, AbbVie’s federal political contributions, which include contributions to re-election committees, leadership political action committees, national political action committees and national political party committees, have historically been evenly split between Democratic and Republican organizations. Many of the recipients of AbbVie’s political contributions engage on a broad range of issues in the course of their regular work, some of which have a direct impact on AbbVie and the patients AbbVie serves, while others are not directly related to AbbVie or the biopharmaceutical industry.
\r\nAll AbbVie corporate and AbbVie PAC political contributions are vetted through a rigorous process that includes:
\r\n1. AbbVie federal and state Government Affairs representatives vetting candidates and submitting proposals to Government Affairs leadership
\r\n2. An internal review to confirm that the contribution meets AbbVie’s giving criteria and is within the approved budget, and to assess the reputational risk of making the contribution
\r\n3. An external compliance review to ensure the contribution is permissible in the relevant jurisdiction
\r\n4. The Senior Vice President, Government Affairs reviewing and approving each contribution
\r\n5. AbbVie Finance confirming financial controls and policies have been complied with for all political contributions.
\r\nWhen available, AbbVie will provide links to AbbVie’s corporate contributions to political candidates, political parties, political committees, ballot measure committees, and organizations operating under 26 USC Sec. 527 of the Internal Revenue Code. AbbVie’s corporate political contribution reports are updated every six months and are archived for reference.
\r\nJan – Dec 2022 Corporate Political Contributions
\r\n
\r\nJan – Dec 2021 Corporate Political Contributions
\r\n
\r\nJan – Dec 2020 Corporate Political Contributions
\r\n
\r\nJan – Dec 2019 Corporate Political Contributions
\r\n
\r\nJan – Dec 2018 Corporate Political Contributions
\r\n
\r\nJan – Dec 2017 Corporate Political Contributions
\r\n
\r\nJan – Dec 2016 Corporate Political Contributions
\r\n
\r\nJan – Dec 2015 Corporate Political Contributions
\r\n
\r\nJan – Dec 2014 Corporate Political Contributions
\r\n
\r\nJan – Dec 2013 Corporate Political Contributions
Our membership in trade associations
\r\nAbbVie belongs to trade associations that represent a broad range of policy issues impacting the company and patients. AbbVie works with its trade associations to ensure AbbVie’s positions are understood and represented within each trade association. Given that these trade associations represent numerous and diverse members, AbbVie understands that we may not always agree with every position a trade association takes. In these circumstances, AbbVie conveys, as appropriate, any concerns through our colleagues who serve on the boards and committees of these associations. We may recuse ourselves from an activity or initiative when appropriate or when we have a divergent point of view.
\r\nFurthermore, AbbVie regularly reviews its trade association memberships on the basis of several factors, including but not limited to congruency on key issues, priorities, initiatives, and overall alignment. After an annual review process in late 2022, AbbVie made the decision to leave select trade associations. For 2023, the U.S. Chamber of Commerce is the largest trade association lobbying at the federal level to which AbbVie belongs. AbbVie has assessed our alignment with the U.S. Chamber of Commerce on the key topics critical to AbbVie's business, including intellectual property, access to healthcare, and tax, and is confident that there is alignment between the Chamber’s stated positions and our positions on these issues.
\r\nThe major U.S. trade associations to which AbbVie provides $25,000 or more in annual membership dues, and which lobby in the U.S. at the federal level may be found here. AbbVie also posts a list of trade associations around the world where an AbbVie employee serves on the organization’s board of directors, which are listed here. The Public Policy and Sustainability Committee of the AbbVie Board of Directors also reviews these memberships.
\r\nOur engagement with governments outside the U.S.
\r\nAbbVie's global affiliates may participate in the political process in their local jurisdictions where permitted by law. These activities are subject to the laws and public disclosures of the relevant jurisdiction and governing body. Information about AbbVie’s lobbying activities in the European Union can be found here.
\r\n"}}" id="text-67e0e077ad" class="cmp-text">我们与美国联邦政府和州政府的合作
AbbVie公共政策参与的是遵循以下原则:
- AbbVie致力于透明度和引导我们代码的商业行为在所有公共政策参与。
- AbbVie追求形状政策受益的病人的活动,重点是提高病人获得新的医学进步。
- AbbVie联邦和各州政府事务代表参与政治参与年度伦理和法律培训。
此外,AbbVie不;
- 提供政治献金的预期,在承认,或以换取正式的行为;
- 寻求或获得直接或间接补偿个人政治捐款或费用;
- 压力或强迫同事个人政治捐款;或者,
- 奖励员工或就业做决定全部或部分基于员工的个人政治捐款。
华盛顿特区的联邦政府事务办公室负责宣传活动与美国国会和联邦政府。宣传在美国各州是由我们的政府事务管理功能。AbbVie还雇佣外部公司,可以提供专业知识对我们关键的政策问题。AbbVie目前并不直接支出对美国联邦和州草根游说通信向公众。此外,AbbVie目前并不提供资金用于选举501 (c)(4)组织,但这样的贡献应该在未来,这将是与AbbVie其他上市公司政治捐款。
AbbVie董事会的公共政策和可持续发展委员会练习AbbVie政治支出的监督和游说活动,作为委员会的章程具体列举,并进一步由政治捐款政策委员会的批准。公共政策和可持续发展委员会和AbbVie的高级管理层定期回顾这些活动和支出。在美国,符合游说披露行为,AbbVie将提交一份季度报告,包括:(i)的总联邦游说开支,(ii)特定政策法规的名称或主题的话题交流,(3)披露AbbVie个人代表AbbVie游说立法机构和(iv)识别或行政部门联系。这份报告包含了与游说联邦政府相关费用,包括联邦政府事务办公室和部分行业协会会费与联邦游说。我们最新的联邦游说信息披露文件中可以找到的美国参议院办公室公共记录的网站和美国众议院办公室职员的网站。我们文件类似的公开游说与状态报告,按照法律的要求,可用在这里。
AbbVie倡导者在一系列问题上在美国,包括:
- 促进病人访问他们的临床医生规定的药物治疗
- 减少病人赔钱的成本
- 强大的知识产权保护
- 奖励创新
政府事务高级副总裁,练习监督所有外部供应商代表AbbVie游说和定期更新的公共政策和可持续发展委员会关于AbbVie AbbVie董事会的游说的优先事项。
我们的报告在政治献金
AbbVie参与政治进程,导致美国联邦、州和地方候选人和政治组织。我们支持候选人和组织,了解政府行为如何影响病人的医疗进步,将努力促进一个促进继续医学进步的环境。下面将更详细地讨论,这种支持是通过两种机制:(1)企业直接从AbbVie政治捐款和(2)AbbVie政治行动委员会的政治捐款执导。
贡献办公室持有者和两党候选人,根据一些标准:政策立场反映AbbVie关键的利益相关的宣传重点;表示的地理区域AbbVie员工和设施;有关立法委员会的任务;当选的能力;和需要金融援助。AbbVie私人政治倾向的高管或其他员工不参与企业政治基金是如何度过的。
政府事务高级副总裁,审查和批准所有企业政治捐款AbbVie政府事务功能的建议,以确保这些贡献是一致的与公司的指导方针和依照适用法律的要求企业政治献金的政策。公共政策和可持续发展委员会AbbVie董事会审查企业政治捐款政策每三年或更频繁,定期听取了由AbbVie政治贡献。
内部政治行动委员会(PAC)董事会指导AbbVie PAC。PAC董事会由高级副总裁主持,政府事务,由至少十二个高级领导人在AbbVie代表广泛的功能。AbbVie PAC董事会成员拥有广泛的经验和观点,通知AbbVie PAC的活动。直接链接到AbbVie PAC的贡献可以在联邦选举委员会的网站上在这里。
AbbVie PAC和直接的企业政治捐款支持广泛的候选人和委员会代表两个主要政党和独立候选人和委员会。例如,AbbVie联邦政治捐款,其中包括贡献连任委员会,领导政治行动委员会,国家政治行动委员会和国家政党委员会,历来是平均分布在民主党和共和党的组织。AbbVie的接受者的许多政治捐款参与广泛的问题在他们的日常工作,其中一些有直接影响AbbVie和病人AbbVie服务,而另一些则不是AbbVie直接相关或生物制药行业。
AbbVie企业和AbbVie PAC政治捐款都是通过严格的审查过程,包括:
1。AbbVie联邦和各州政府事务代表审查候选人和政府事务的领导提交建议
2。内部审核确认符合AbbVie给标准的贡献和在批准的预算,并评估声誉风险的贡献
3所示。外部合规审查,以确保有关管辖权的贡献是允许的
4所示。政府事务高级副总裁,审查和批准每一个贡献
5。AbbVie财务确认金融管制和政策已经遵守了所有的政治捐款。
当可用时,AbbVie将提供链接AbbVie对政治候选人的企业贡献,政党、政治委员会,选举委员会和组织操作在南加州大学26秒。527年《国内税收法典》。AbbVie报告企业的政治贡献每六个月更新一次,并存档备查。
2022年1月- 12月企业政治捐款
2021年1月- 12月企业政治捐款
2020年1月- 12月企业政治捐款
2019年1月- 12月企业政治捐款
2018年1月- 12月企业政治捐款
2017年1月- 12月企业政治捐款
2016年1月- 12月企业政治捐款
2015年1月- 12月企业政治捐款
2014年1月- 12月企业政治捐款
2013年1月- 12月企业政治捐款
我们在贸易协会会员
AbbVie属于行业协会代表广泛的政策问题影响公司和病人。AbbVie贸易协会一起工作,以确保AbbVie职位的理解和在每一个贸易协会表示。考虑到这些行业协会代表众多多样化的成员,AbbVie明白我们可能并不总是同意每个位置一个贸易协会。适当的,在这种情况下,AbbVie传达任何问题通过我们的同事在这些协会的董事会和委员会服务。我们可能要求撤换自己从一个活动或计划在适当的时候或者当我们有不同的观点。
此外,AbbVie定期审查其贸易协会会员的基础上几个因素,包括但不限于在关键问题上一致,重点,计划,和整体一致性。在2022年度审查过程后,AbbVie决定离开选择贸易协会。2023年,美国商会(U.S. Chamber of Commerce)是最大的贸易协会游说AbbVie所属在联邦政府层面。AbbVie评估我们与美国商会(U.S. Chamber of Commerce)的关键主题AbbVie至关重要的业务,包括知识产权,获得医疗保健,和税收,有信心,有室之间的对齐的既定立场和我们在这些问题上的立场。
美国主要贸易协会,AbbVie每年提供25000美元或更多的会费,并游说在美国在联邦政府层面可以发现在这里。AbbVie还帖子列表世界各地的贸易协会,一个AbbVie员工是组织的董事会,列出在这里。公共政策和可持续发展委员会AbbVie董事会也评论这些会员。
我们与政府在美国以外的接触
AbbVie全球子公司可能参与政治进程的地方政府在法律允许的情况下。这些活动受到法律和公众披露有关管辖权和管理机构。AbbVie的游说活动信息可以找到在欧盟在这里。
我们的指导原则和患者团体一起工作
We partner with patient groups at the highest level of transparency and integrity. We’ve established these principles to ensure a common understanding of the way we work with patient groups.\r\n
Independence
\r\nThe independence of patient groups will not be compromised. AbbVie encourages patient groups to maintain relationships with a wide range of organizations and companies.
\r\nTransparency
\r\nAll support will be disclosed according to relevant laws and patient groups will recognize company support through locally appropriate means. Both AbbVie and patient groups will have final approval on all public uses of their respective name, logo and identifying symbols.
\r\nTrust and mutual respect
\r\nThrough a mutual and open understanding of each other’s policies, objectives and working practices, AbbVie will demonstrate respect for our partners as we each work toward common desired outcomes. When providing information on marketed and investigational medicines, AbbVie will do so in compliance with applicable local laws, regulations, policies and procedures.
\r\n"}}" id="text-bdeb5c10fd" class="cmp-text">我们与患者合作组在最高水平的透明度和完整性。我们的这些原则,以确保建立一个共同的理解我们的工作方式与病人组织。
独立
独立的患者团体将不会妥协。AbbVie鼓励患者团体维持关系与广泛的组织和公司。
透明度
所有支持将披露根据有关法律和病人团体将识别公司通过当地合适的手段支持。AbbVie和患者团体将会对所有公共最终批准使用各自的名称、标志和识别符号。
信任和相互尊重
通过相互开放、相互理解的政策,目标和工作实践,AbbVie将展示尊重我们的合作伙伴,我们每个人都努力共同想要的结果。当提供市场信息和临床实验的药品,AbbVie将按照适用的当地法律,法规,政策和程序。
加州供应链行为的透明度
AbbVie believes in being a socially responsible company and doing what is right, not just by our customers, but by the world in which we live. AbbVie is committed to safe and fair working conditions, beyond our employees and the stores in which our products are sold, but also extending to the partners in our supply chain. AbbVie has a global policy against trafficking and slavery in supply chains. AbbVie engages in verification of product supply chains to evaluate and address risks of human trafficking and slavery. The verification is conducted by AbbVie employees in AbbVie Purchasing and Supplier Management. Additionally, AbbVie or a third party that is independent of supply chain management conducts audits of suppliers (usually announced ahead of time) to evaluate supplier compliance with company standards for trafficking and slavery.\r\n
AbbVie’s Code of Business Conduct sets forth our commitment to conduct our business with the highest ethical standards and comply with all laws and regulations. AbbVie employees worldwide certify annually on AbbVie’s Code of Business Conduct. AbbVie expects its business partners, such as contract workers, vendors, suppliers and consultants, to adhere to ethical behavior consistent with the spirit of AbbVie’s Code of Business Conduct and to all applicable laws and regulations when working on behalf of AbbVie.
\r\nAbbVie’s Supplier Code of Conduct states our expectations to suppliers conducting business with AbbVie that they are prohibited from engaging in illegal behavior, including human trafficking and slavery. AbbVie requires direct suppliers to certify that materials incorporated into AbbVie’s products comply with local and national laws regarding slavery and human trafficking of the country or countries in which they are doing business. Certifications are also obtained from suppliers that they comply with standards as outlined in our Supplier Code of Conduct. AbbVie will maintain internal accountability standards and procedures for both employees and contractors failing to meet company standards regarding slavery and trafficking.
\r\nEmployees and contractors assigned to AbbVie who fail to abide by AbbVie’s Code of Business Conduct may be subject to reprimand or other adverse consequences, up to and including termination of employment or assignment. AbbVie provides training to its employees and management who have direct responsibility for supply chain management, regarding human trafficking and slavery, particularly with respect to mitigating risks within the supply chains of products.
\r\n"}}" id="text-001273a272" class="cmp-text">AbbVie相信作为一个具有社会责任感的公司,做什么是正确的,不仅仅是我们的客户,但我们生活的世界。AbbVie致力于安全、公平的工作条件,超出了我们的员工和商店出售我们的产品,而且还扩展到供应链中的合作伙伴。AbbVie全球政策反对人口贩卖和奴役在供应链。AbbVie从事验证产品供应链的评价和解决人口贩卖和奴役的风险。验证是由AbbVie员工AbbVie采购和供应商管理。此外,AbbVie或独立的第三方供应链管理对供应商进行审计(通常是提前宣布)来评估供应商遵守公司标准贩卖和奴役。
AbbVie的商业行为准则阐述我们的承诺进行我们的业务最高的道德标准和遵守所有法律和法规。AbbVie员工每年全球认证AbbVie的商业行为准则。AbbVie预计其业务合作伙伴,如合同工人、供应商、供应商和顾问,坚持道德行为一致的精神AbbVie的商业行为准则和所有适用的法律、法规时代表AbbVie工作。
AbbVie的供应商行为准则我们的期望与AbbVie供应商做生意,他们被禁止从事非法行为,包括人口贩卖和奴役。AbbVie要求直接供应商证明材料纳入AbbVie产品符合当地和国家法律关于奴隶制和贩卖人口的国家或国家做生意。认证也从供应商获得,他们符合标准中列出我们的供应商行为准则。AbbVie将保持内部问责标准和程序对员工和承包商未能达到公司标准关于奴役和人口贩卖。
员工和承包商分配给AbbVie未能遵守AbbVie的商业行为准则可能会受到谴责或其他不良后果,包括终止就业或任务。AbbVie提供培训员工和管理直接负责供应链管理,关于人口贩卖和奴役,尤其是对减轻风险的供应链内的产品。
加州行动宣言
AbbVie’s ethics and compliance program (the “Program”) reflects our commitment to compliance with the laws and regulations applicable to our business, including the California Health and Safety Code §§119400-119402 (the “California Act”). Interested parties may view the Program online or may also call 800-254-0462 for a copy of any of the Program materials.\r\n
In accordance with the California Act, AbbVie has established a specific annual dollar limit of $2,500, which applies to promotional materials, items and activities provided to covered recipients in California. In addition, the following expenses are excluded from the limit: expenses that are directly associated with payments statutorily excluded from the limit (e.g., meals for consultants), items provided to health care professionals that are ultimately intended for patients or consumers, fellowships, receptions at third-party educational or professional meetings, and sales aids. To the best of its knowledge, AbbVie declares that as of March 31, 2023, it is in all material respects in compliance with the requirements of the California Act.
\r\n"}}" id="text-53df44b607" class="cmp-text">AbbVie的道德与合规计划(“计划”)反映了我们的承诺,遵守法律法规适用于我们的业务,包括加州健康和安全代码§§119400 - 119402(“加州法案”)。感兴趣的可能查看程序在线或者也可以叫800-254-0462程序的任何材料的副本。
按照加州法案,AbbVie建立了一个特定的美元每年2500美元的限制,适用于宣传材料,项目和活动提供给收件人在加州。此外,排除在极限以下费用:费用与支付法定排除在直接相关的限制(例如,餐顾问),项目提供卫生保健专业人士最终用于患者或消费者,奖学金,在第三方教育或专业会议接待,销售艾滋病。最好的知识,AbbVie宣称截至3月31日,2023年,它是在所有材料方面符合加州法案的要求。
加州抗专家计划
AbbVie’s HUMIRA (adalimumab) Sharps Mail-Back Program\r\n"}}" id="text-93f1e78194" class="cmp-text">
AbbVie卫生保健提供者和供应商通知
AbbVie collects information, including personally identifying information, relating to customers, medical and health care professionals, industry experts and opinion leaders, consumers, suppliers, service providers, business partners and vendors with whom AbbVie has a business or commercial relationship. To learn more, please click here.\r\n"}}" id="text-f26ce02804" class="cmp-text">
AbbVie收集信息,包括个人身份信息,有关客户、医疗卫生专业人士、行业专家意见领袖、消费者、供应商、服务提供商、业务合作伙伴和供应商一起AbbVie业务或商业关系。请了解更多点击这里。
知识产权和病人的访问
At AbbVie, R&D centers around the patient, from understanding disease biology to treatment delivery, clinical trials, and beyond. We combine our experience pioneering scientific breakthroughs, the best ideas in science, and advanced technologies to develop the next generation of medicines.\r\n
Each year we spend billions on R&D, enabling us to discover and deliver innovative medicines and products that solve serious health issues and enhance people’s lives today and address the medical challenges of tomorrow.
\r\nIntellectual property, in particular patents, is critical to protecting the significant investments that allow AbbVie to solve these serious health issues. Patents ensure that we are able to recoup investments, not only in the initial creation of a medicine itself, but also in AbbVie’s ongoing investment in that medicine – for example, by studying it in new patient populations and diseases over time, by optimizing the process used to manufacture the medicine, and by improving the formulation of the medicine over time to better meet patient needs. Patents also allow us to re-invest in developing new medicines, further improving patients’ standard of care over time.
\r\nWhen AbbVie assesses whether to apply for a patent to cover a certain innovation, we consider many factors. First, science is at the heart of everything we do at AbbVie, including our decisions related to patents. AbbVie pursues patents that reflect meaningful innovation and scientific advancements, including those that have the potential to improve the treatment of patients. Such innovation may improve the safety and efficacy of patient care and the quality and efficiency of AbbVie’s manufacturing processes. Second, in evaluating intellectual property, we carefully consider the technology, the state of the art, and patent laws of the relevant jurisdiction. Third, AbbVie considers the value of our public disclosure in advancing science. Finally, we take into account the size of the underlying investment and the impact on patient access. We believe considering these factors, and others, can both protect AbbVie’s investments and further patient access to innovative new medicines.
\r\nAbbVie has an established history of granting patent licenses under appropriate circumstances, in order to facilitate broader global access to our medicines. AbbVie’s patient support and assistance programs further demonstrate our commitment to patient access and meeting unmet need.
\r\nAbbVie’s intellectual property processes are overseen by AbbVie’s Executive Vice President, General Counsel and Vice President, Intellectual Property and Strategy and R&D. The Board of Directors also oversees AbbVie’s intellectual property strategy, as well as AbbVie’s approach to patient access.
\r\nAbbVie participates in numerous external collaborations and projects dedicated to furthering the responsible use of intellectual property. For example, AbbVie is a signatory for IP Principles for Advancing Cures and Therapies (IP PACT) and participates in Pat-INFORMED (Patent Information Initiative for Medicines).
\r\n"}}" id="text-a0ea68a091" class="cmp-text">AbbVie,研发中心的病人,从理解疾病生物治疗,临床试验和超越。我们结合我们的经验开创性的科学突破,科学,最好的想法和先进技术开发新一代的药物。
我们每年在研发上投入数十亿美元,使我们能够发现并提供创新药物和产品,解决严重的健康问题,提高人们的生活今天和地址的医疗挑战明天。
知识产权,尤其是专利,保护至关重要的重要投资,允许AbbVie解决这些严重的健康问题。专利确保我们能够收回投资,不仅在最初创建一个医学本身,而且在AbbVie的在建投资医学——例如,通过研究在新患者群体和疾病随着时间的推移,通过优化流程用于生产药物,随着时间的推移,通过改善药的配方,以更好地满足病人的需求。专利也允许我们再投资开发新药物,进一步提高患者的标准治疗。
当AbbVie评估是否申请专利覆盖一定的创新,我们考虑很多因素。首先,科学的核心在AbbVie我们所做的一切,包括我们的决定有关的专利。AbbVie追求专利反映意义的创新和科学的进步,包括那些有潜力改善病人的治疗。这些创新可以改善病人护理的安全性和有效性,AbbVie的制造过程的质量和效率。第二,在评估知识产权,我们仔细考虑技术、艺术的状态和专利相关法律管辖。第三,AbbVie认为我们的公共信息披露在推进科学的价值。最后,我们考虑潜在的投资和的大小影响病人的访问。我们相信,考虑到这些因素,和其他人,既能保护AbbVie的投资,进一步病人获得创新药物。
AbbVie的建立历史授予专利许可在适当的情况下,为了促进更广泛的全球访问我们的药品。AbbVie耐心的支持和援助项目进一步证明我们的承诺,病人访问和会议未满足的需求。
AbbVie的知识产权过程是由AbbVie的执行副总裁,首席法律顾问和副总统、知识产权战略和研发。董事会还监督AbbVie的知识产权战略,以及AbbVie病人的方法访问。
AbbVie参与众多外部协作和项目致力于知识产权促进负责任的使用。例如,AbbVie签署IP推进治疗原则和治疗方法(IP协议)和参与Pat-INFORMED(药品专利信息计划)。
额外的资源
U.S. Senate Office of Public Records
\r\n
\r\nU.S. House of Representatives Office of the Clerk
\r\n
\r\nFederal Election Commission\r\n"}}" id="text-1f9d812650" class="cmp-text">
\r\n
\r\nU.S. House of Representatives Office of the Clerk
\r\n
\r\nFederal Election Commission\r\n"}}" id="text-1f9d812650" class="cmp-text">
外部链接
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.\r\n
Copyright © 2023 AbbVie Inc. North Chicago, Illinois, U.S.A.
\r\n"}}" id="text-3a1364a84d" class="cmp-text">除非另有规定,所有产品名称出现在本网站商标或许可AbbVie Inc .旗下的子公司或分支机构。没有使用任何AbbVie商标,商号,或贸易服装在这个网站可能没有AbbVie Inc .的事先书面授权,除了确定公司的产品或服务。
版权©2023 AbbVie Inc .北芝加哥,伊利诺斯州,美国
